Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart reviewReview article Published on 2022-05-012022-10-05 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 진단, [키워드] cellular complications coronavirus 2019 (COVID-19) coronavirus disease COVID-19 COVID-19 mRNA vaccine COVID-19 myocarditis COVID-19 perimyocarditis COVID-19 vaccination disease Healthcare system Hospitalization hypothetical Mortality mRNA vaccine mRNA vaccines myocarditis pandemic Pathogenesis pathogenesis of COVID-19 pathophysiology post vaccination reduced regimen reported SARS-CoV-2 Severe COVID-19 Infection Side effect Side-effect significantly Takotsubo syndrome therapeutic with COVID-19 [DOI] 10.1016/j.biopha.2022.112843 [Article Type] Review article
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA VaccinationBNT162b2 COVID-19 mRNA 백신 접종 후 6개월 후의 SARS-CoV-2 변이체에 대한 백신 유도 항체 반응Article Published on 2022-04-272022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Alpha anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody antibody levels Beta BNT162b2 BNT162b2 vaccine booster dose booster doses collected coronavirus COVID-19 COVID-19 disease COVID-19 mRNA vaccine COVID-19 mRNA vaccines D614G decrease Delta delta variant detectable dose effective Efficacy Eta fold Health care Health care worker immune evasion immune responses Lineage Month mRNA mRNA vaccine mRNA vaccines neutralization neutralize neutralized Neutralizing Neutralizing antibodies new virus of BNT162b2 persistence postvaccination raised receiving reduced reduction respiratory response responses SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 variant sera severe acute respiratory syndrome Coronavirus severe COVID-19 disease specific antibodies Transmissibility vaccination Vaccination strategies Vaccination strategy Vaccine vaccine efficacy vaccinees Vaccines variant variants [DOI] 10.1128/spectrum.02252-21 PMC 바로가기 [Article Type] Article
Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection – United States, June 2021-February 2022이전 SARS-CoV-2 감염이 있는 성인의 COVID-19 관련 입원 예방에 대한 COVID-19 mRNA 백신 접종의 효과 - 미국, 2021년 6월-2022년 2월Article Published on 2022-04-152022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Analysis booster dose cause Cosmos COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines data set diagnosis of COVID-19 dose Effectiveness Electronic health record eligible Health health record highest Hospitalization infection with SARS-CoV-2 mRNA NAAT nucleic acid nucleic acid amplification omicron Omicron variant positive Prevent Preventing provide Reinfection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant subsequent United States used data vaccination Vaccination Status Vaccine vaccine dose variant virus was used [DOI] 10.15585/mmwr.mm7115e2 PMC 바로가기 [Article Type] Article
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA VaccinationmRNA 백신 접종 후 SARS-CoV-2 변이체의 RBD에 대한 감소된 이종 중화 항체 반응Article Published on 2022-04-062022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] accumulate ACE2 acute respiratory syndrome Against Alpha analyzed Antibody neutralization approaches B.1.1.7 B.1.427 B.1.617.1 B.1.617.2 binding BNT162b2 BNT162b2 mRNA Cohort coronavirus coronavirus 2 COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines Decreased Delta domain dose E484K/Q mutation Epsilon evade FIVE flow cytometry Gamma healthcare worker Healthcare workers healthcare workers (HCW) heterogeneity highest immune protection knowledge L452R magnitude Moderna mRNA mRNA vaccine mRNA vaccines mRNA1273 Mutation naïve individual naïve individuals natural infection Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibodies (NAB) neutralizing antibody neutralizing response P.1 Pfizer-BioNTech provided raise RBD RBD of SARS-CoV-2 RBD variant receiving Receptor binding domain receptor binding domain (RBD) Receptor-binding domain regimen respiratory response SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significant increase significantly higher specific neutralizing antibodies Spike protein Spread subject subsequent tested the RBD vaccinated individuals vaccination Vaccine vaccine doses Vaccine-induced immunity variant Viral viral spike protein viral variant Viral variants Wuhan strain [DOI] 10.3389/fimmu.2022.816389 PMC 바로가기 [Article Type] Article
COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant womenArticle Published on 2022-04-042022-11-01 Journal: Science Translational Medicine [Category] COVID-19, MERS, SARS, [키워드] antibody BNT162b2 vaccine breastmilk change changes changes in comparable contribute controls COVID-19 COVID-19 mRNA vaccine Critical develop fetal function growth humoral immune response immune system Immunity immunological immunological change indicate induce Infection Inflammatory lactating lactating women lactation less Local mother mRNA-1273 normalized occur pathogen physiological Pregnancy pregnant pregnant women profile promote PROTECT receptor second dose severe coronavirus disease susceptibility timeline Tolerance vaccination vaccine dose vaccine response women [DOI] 10.1126/scitranslmed.abi8631 PMC 바로가기 [Article Type] Article
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records전자 건강 기록을 사용한 COVID-19 mRNA 백신 3회 접종의 안전성 감시Article Published on 2022-04-012022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI addition Administered Adverse adverse event adverse events age analyzed anaphylaxis approval arthralgia BNT162b2 booster vaccination booster vaccinations chill clinical trials Cohort cohort study cohorts comparable conducted control groups COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines criteria diarrhea dose drug EHR eligible evaluate fatigue Fever food headache Health increased risk individual individuals Mayo Clinic median mRNA mRNA vaccine mRNA-1273 myalgia myocarditis nausea outcome participant profile quantified receiving recent Record regimen remained reported Reporting risk Safety SARS-COV-2 infection second dose severe adverse event study inclusion study participant thrombosis vaccination Vaccine vaccine dose Vaccine-induced immunity venous vomiting was tested were assessed [DOI] 10.1001/jamanetworkopen.2022.7038 PMC 바로가기 [Article Type] Article
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death – United States, March 2021-January 2022COVID-19 관련 침습적 기계적 환기 및 사망 예방에 대한 mRNA 백신 접종의 효과 - 미국, 2021년 3월-2022년 1월Article Published on 2022-03-252022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] 변종, [키워드] 95% CI Alpha B.1.1.529 B.1.1.7 B.1.617.2 BNT162b2 Case-control cause CDC circulating variant control patient COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines COVID-19 vaccination death Delta died dose doses effective Effectiveness eligible enrolled evaluated had more Hospitalization hospitalizations Hospitalized illness onset Immunocompromised IMV In-hospital death Invasive mechanical ventilation Mechanical median age medical condition Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 Older omicron outcome Pfizer-BioNTech Preventing PROTECT Respiratory failure SARS-CoV-2 treated United States vaccination vaccine dose vaccine doses virus with COVID-19 [DOI] 10.15585/mmwr.mm7112e1 PMC 바로가기 [Article Type] Article
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysisReview article Published on 2022-03-012022-10-05 Journal: The Journal of Infection [Category] SARS, 변종, 진단, [키워드] 95% CI anti-SARS-CoV-2 antibody production calculated control group controls COVID-19 COVID-19 infection COVID-19 mRNA vaccine COVID-19 vaccine Diagnosis diagnostic effective Effectiveness groups healthy IgG IgG antibody Immunocompromised Immunocompromised patient Immunocompromised patients Inflammatory investigated laboratory-confirmed literature review malignant disease Medical conditions Meta-analysis much higher objective Odds ratio Prevent Research Result rheumatic disease solid organ transplant Spike protein stratified symptomatic [DOI] 10.1016/j.jinf.2021.12.035 [Article Type] Review article
Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination증가된 인터루킨 18 의존성 면역 반응은 COVID-19 mRNA 백신 접종 후 심근염과 관련이 있습니다Immunology Published on 2022-02-182022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] abnormality activated Activation administration Cardiac complications caused CD68 Cell characterized chest pain circulating Control controls COVID-19 COVID-19 mRNA Vaccination COVID-19 mRNA vaccine COVID-19 vaccination cytokine Cytokines disease onset dysfunction elevated expressed first dose Flow cytometry analysis healthy individual hearts IL-18 IL-27 Immune profile immune response incidence Increased individuals infiltration interleukin interleukin 18 mechanism mice Mild monocyte mRNA mRNA-1273 COVID-19 vaccine multiplex Myopericarditis NK cell NK cells NLRP3 inflammasome occur Patient phenotype progression response T cell Th1-type immune response the patient troponin I upstream vaccinated individual vaccination were used with COVID-19 [DOI] 10.3389/fimmu.2022.851620 PMC 바로가기 [Article Type] Immunology
The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World DataArticle Published on 2022-02-172022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI Adverse adverse event AEs analyzed anaphylaxis BNT162b2 close monitoring coagulation disorders COVID-19 COVID-19 infections COVID-19 mRNA vaccine COVID-19 vaccine Effect females Guidance individual injection JNJ-78436735 male management median time monitoring mRNA COVID-19 vaccine mRNA vaccines mRNA-1273 Pfizer-BioNTech provided real-world data reported Reporting risk Safety severe adverse events severe AE severe and common significantly higher System Vaccine Vaccines Viral vector vaccine [DOI] 10.3390/vaccines10020320 PMC 바로가기 [Article Type] Article